The Cool Chain Association has said that logistics providers in the pharmaceutical supply chain community must “collaborate with regulators to set global standards”.
The association said that a “unified approach” is necessary to tackle the changing needs of the cool chain shipper, as well as to “help to combat annual losses of up to $35 billion resulting from wasted pharmaceutical product temperature excursions”.
“Temperature controlled logistics is expected to grow by nine per cent every year, leading to a global cool chain industry worth around USD16.7 billion by 2020,” said Sebastiaan Scholte, chairman, CCA at the recent Pharma and Biosciences Conference. “However, the patchwork of regulations around the world, as well as the huge amount of data being collected as we process pharma goods, means we have to navigate a highly complex system.
“Open dialogue between industry and regulators is vital to ensure every voice in the cool chain is heard to help us achieve a slicker, more transparent supply chain that meets the evolving needs of the pharmaceutical marketplace.”